Janus Kinase Inhibitor Found 71% Effective Against SARS-CoV-2 Pneumonia

A new study in Italy published on November 13, 2020, found Baricitinib as possessing anti-viral and anti-cytokine efficacy. This limited study showed a 71% (95% CI 0.15-0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia, with few drug-induced adverse events, including a large elderly cohort (median age 81 years).

And, a further 48 cases with mild-moderate pneumonia recovered uneventfully.